Cryo-Cell International, Inc. (CCEL) Key Metrics
CCEL valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $35.6M
- Enterprise value
- $38.0M
- P/E (TTM)
- — 10-yr median 27.2
- Forward P/E
- —
- PEG ratio
- 1.34
- Price / sales
- 1.1 10-yr median 1.9
- Price / book
- 9.7
- EV / EBITDA
- 50.9 10-yr median 12.0
- Dividend yield
- —
- Beta
- 0.59
CCEL key metrics, FY2016–FY2025
Fiscal year ended November 30, 2025 · U.S. dollarsCCEL valuation Price multiples at each fiscal year-end price.
Price / sales−50.6%
1.1
FY2025 · hover or tap a bar for each year
FY2016FY2025
EV / EBITDA−4.8%
39.2
FY2025 · hover or tap a bar for each year
FY2016FY2025
Price / free cash flow−77.6%
6.6
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow yield+11.7 pts
15.1%
FY2025 · hover or tap a bar for each year
FY2016FY2025
CCEL returns How much profit the business earns on the capital it uses.
Return on assets−4.5 pts
−3.8%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow margin+9.1 pts
16.6%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Asset turnover−1.7%
0.50
FY2025 · hover or tap a bar for each year
FY2016FY2025
CCEL per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+0.4%
$3.91
FY2025 · hover or tap a bar for each year
FY2016FY2025
Earnings per share
−$0.30
FY2025 · hover or tap a bar for each year
FY2016FY2025
Free cash flow per share+121.9%
$0.65
FY2025 · hover or tap a bar for each year
FY2016FY2025
Book value per share
−$2.31
FY2025 · hover or tap a bar for each year
FY2016FY2025
Dividends per share+62.8%
$0.40
FY2025 · hover or tap a bar for each year
FY2016FY2025
Shares outstanding−1.8%
8.1M
FY2025 · hover or tap a bar for each year
FY2016FY2025
CCEL financial health Debt, liquidity and how easily interest is covered.
Net debt−$1.2M
$8.3M
FY2025 · hover or tap a bar for each year
FY2016FY2025
Net debt / EBITDA+2.72
7.53
FY2025 · hover or tap a bar for each year
FY2016FY2025
Current ratio+2.2%
0.59
FY2025 · hover or tap a bar for each year
FY2016FY2025
Interest coverage+25.5%
2.3
FY2025 · hover or tap a bar for each year
FY2016FY2025
Debt / assets−6.4%
0.19
FY2025 · hover or tap a bar for each year
FY2016FY2025
CCEL efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding+3 days
82 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Days of inventory−6 days
26 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Days payables outstanding+1 days
118 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Cash conversion cycle−5 days
-9 days
FY2025 · hover or tap a bar for each year
FY2016FY2025
Capex / revenue−10.5 pts
0.7%
FY2025 · hover or tap a bar for each year
FY2016FY2025
Dividends + buybacks / FCF−78.3 pts
64.8%
FY2025 · hover or tap a bar for each year
FY2016FY2025
CCEL valuation history
Fiscal year-endToday10-year median
CCEL returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
CCEL debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
CCEL cash returned to shareholders
DividendsBuybacksFree cash flow
CCEL price vs earnings per share
Share price at year-endEPS (right axis)
CCEL key metrics
FY2016–FY2025| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $34.7M | $71.2M | $44.6M | $37.1M | $103.5M | $61.1M | $63.5M | $54.6M | $61.7M | $34.5M |
| Enterprise value | $43.0M | $80.6M | $54.5M | $47.0M | $98.0M | $56.8M | $65.0M | $60.7M | $62.3M | $40.2M |
| P/E ratio | — | 177.1 | — | 13.4 | 49.7 | 16.8 | 27.7 | — | 26.6 | — |
| Price / sales | 1.1 | 2.2 | 1.4 | 1.2 | 3.6 | 2.0 | 2.0 | 1.9 | 2.4 | 1.5 |
| Price / book | — | — | — | — | 24.7 | — | — | — | — | — |
| Price / free cash flow | 6.6 | 29.6 | 34.8 | — | 106.2 | 7.6 | 11.2 | 11.7 | 11.0 | 7.4 |
| Price / operating cash flow | 6.3 | 11.8 | 5.0 | 4.3 | 13.1 | 7.2 | 10.0 | 10.2 | 10.8 | 6.9 |
| EV / sales | 1.4 | 2.5 | 1.7 | 1.5 | 3.4 | 1.8 | 2.0 | 2.1 | 2.5 | 1.7 |
| EV / EBITDA | 39.2 | 41.1 | — | 7.1 | 18.4 | 7.9 | 11.8 | 11.1 | 12.1 | — |
| EV / free cash flow | 8.2 | 33.5 | 42.6 | — | 100.5 | 7.1 | 11.5 | 12.9 | 11.1 | 8.6 |
| Earnings yield | −7.0% | 0.6% | −21.3% | 7.5% | 2.0% | 5.9% | 3.6% | −1.6% | 3.8% | −3.8% |
| Free cash flow yield | 15.1% | 3.4% | 2.9% | −23.2% | 0.9% | 13.1% | 8.9% | 8.6% | 9.1% | 13.5% |
| Dividend yield | 9.3% | 2.8% | 0.0% | 20.7% | 0.0% | — | — | 0.0% | 0.0% | 0.0% |
| Shareholder yield (dividends + buybacks) | 9.8% | 4.8% | 1.8% | 25.6% | 0.2% | 0.0% | 1.6% | 0.0% | 0.7% | 31.3% |
| Share price at fiscal year-end | $4.30 | $8.67 | $5.35 | $4.37 | $12.38 | $7.50 | $7.55 | $7.32 | $8.06 | $4.25 |
| Per share | ||||||||||
| Revenue per share | $3.91 | $3.89 | $3.76 | $3.58 | $3.45 | $3.83 | $3.78 | $3.92 | $3.32 | $2.85 |
| Earnings per share | −$0.30 | $0.05 | −$1.14 | $0.33 | $0.25 | $0.45 | $0.27 | −$0.11 | $0.30 | −$0.16 |
| Operating cash flow per share | $0.68 | $0.73 | $1.07 | $1.01 | $0.95 | $1.04 | $0.75 | $0.71 | $0.75 | $0.61 |
| Free cash flow per share | $0.65 | $0.29 | $0.15 | −$1.01 | $0.12 | $0.98 | $0.67 | $0.63 | $0.73 | $0.57 |
| Cash per share | $0.41 | $0.43 | $0.12 | $0.20 | $1.00 | $1.28 | $0.89 | $0.93 | $0.88 | $0.51 |
| Book value per share | −$2.31 | −$1.61 | −$1.32 | −$0.18 | $0.50 | −$0.33 | −$0.83 | −$1.19 | −$1.63 | −$1.90 |
| Tangible book value per share | −$2.65 | −$1.96 | −$1.67 | −$2.19 | −$1.67 | −$0.75 | −$1.21 | −$1.63 | −$1.66 | −$1.93 |
| Dividends per share | $0.40 | $0.25 | $0.00 | $0.90 | $0.00 | — | — | $0.00 | $0.00 | $0.00 |
| Capex per share | $0.03 | $0.44 | $0.92 | $2.02 | $0.83 | $0.06 | $0.08 | $0.09 | $0.01 | $0.04 |
| Debt per share | $1.43 | $1.57 | $1.31 | $1.37 | $0.34 | $0.77 | $1.06 | $1.73 | $0.95 | $1.21 |
| Shares outstanding | 8.1M | 8.2M | 8.3M | 8.5M | 8.4M | 8.1M | 8.4M | 7.5M | 7.7M | 8.1M |
| Change in shares outstanding | −1.8% | −1.5% | −1.7% | +1.5% | +2.7% | −3.2% | +12.7% | −2.5% | −5.7% | −17.2% |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | — | — | — | — | 274.3% | — | — | — | — | — |
| Return on invested capital (ROIC) | — | — | — | 95.5% | — | — | — | — | — | — |
| Return on assets (ROA) | −3.8% | 0.6% | −15.1% | 4.4% | 3.9% | 8.1% | 5.4% | −2.6% | 10.7% | −6.8% |
| Return on tangible assets | −4.1% | 0.7% | −16.3% | 5.8% | 4.9% | 8.5% | 5.8% | −2.2% | 9.8% | −6.9% |
| Free cash flow margin | 16.6% | 7.5% | 4.1% | −28.3% | 3.4% | 25.7% | 17.8% | 16.0% | 22.1% | 20.1% |
| Income quality (OCF / net income) | — | 14.95 | — | 3.09 | 3.80 | 2.34 | 2.76 | — | 2.47 | — |
| Financial health | ||||||||||
| Total debt | $11.6M | $12.9M | $10.9M | $11.6M | $2.8M | $6.2M | $9.0M | $12.9M | $7.3M | $9.8M |
| Cash & short-term investments | $3.3M | $3.5M | $980,250 | $1.7M | $8.3M | $10.4M | $7.4M | $6.9M | $6.7M | $4.1M |
| Net debt | $8.3M | $9.4M | $9.9M | $9.9M | −$5.5M | −$4.2M | $1.5M | $6.0M | $576,707 | $5.7M |
| Debt / equity | — | — | — | — | 0.67 | — | — | — | — | — |
| Debt / assets | 0.19 | 0.20 | 0.18 | 0.18 | 0.05 | 0.14 | 0.21 | 0.31 | 0.31 | 0.50 |
| Net debt / EBITDA | 7.53 | 4.81 | — | 1.49 | −1.04 | −0.58 | 0.27 | 1.10 | 0.11 | — |
| Current ratio | 0.59 | 0.58 | 0.45 | 0.49 | 0.75 | 1.13 | 1.00 | 1.91 | 0.91 | 0.69 |
| Quick ratio | 0.57 | 0.55 | 0.42 | 0.45 | 0.71 | 1.07 | 0.93 | 0.87 | 0.89 | 0.66 |
| Interest coverage | 2.3 | 1.9 | -9.9 | 2.6 | 2.9 | 5.0 | 3.0 | 3.4 | 3.8 | 0.5 |
| Working capital | −$8.0M | −$9.0M | −$11.4M | −$9.9M | −$5.3M | $2.1M | −$41,818 | $14.1M | −$1.2M | −$4.1M |
| Invested capital | −$10.3M | −$3.8M | −$1.1M | $8.4M | −$1.3M | −$6.9M | −$5.4M | −$2.9M | −$11.9M | −$9.7M |
| Tangible asset value | −$21.4M | −$16.1M | −$14.0M | −$18.6M | −$14.0M | −$6.1M | −$10.1M | −$12.2M | −$12.7M | −$15.7M |
| Net current asset value | −$68.6M | −$65.3M | −$62.8M | −$56.8M | −$40.7M | −$30.3M | −$34.5M | −$21.8M | −$23.7M | −$25.9M |
| Graham number | — | — | — | — | $1.67 | — | — | — | — | — |
| Graham net-net per share | −$8.89 | −$8.35 | −$7.91 | −$7.04 | −$5.23 | −$4.08 | −$4.43 | −$4.28 | −$3.36 | −$3.40 |
| Capital allocation | ||||||||||
| Dividends paid | $3.2M | $2.0M | $0 | $7.7M | $0 | — | — | $0 | $0 | $0 |
| Share buybacks (net) | $169,502 | $1.4M | $799,036 | $1.8M | $249,377 | $0 | $992,244 | $0 | $446,621 | $10.8M |
| Dividend payout ratio | — | 502.5% | — | 276.9% | 0.0% | — | — | — | 0.0% | — |
| Dividends + buybacks / free cash flow | 64.8% | 143.1% | 62.4% | — | 25.6% | 0.0% | 17.5% | 0.0% | 7.9% | 232.6% |
| Capex / revenue | 0.7% | 11.3% | 24.4% | 56.6% | 24.1% | 1.4% | 2.1% | 2.2% | 0.4% | 1.5% |
| Capex / operating cash flow | 4.2% | 60.0% | 85.6% | 200.3% | 87.7% | 5.3% | 10.5% | 12.1% | 1.7% | 6.9% |
| Capex / depreciation | 0.17 | 3.53 | 4.47 | 9.49 | 5.24 | 0.71 | 1.65 | 2.04 | 0.43 | 1.20 |
| Stock-based compensation / revenue | 1.3% | 2.4% | 2.6% | 1.5% | 1.0% | 2.0% | 1.3% | 1.6% | 3.8% | 7.7% |
| R&D / revenue | 1.2% | 3.9% | 3.7% | 1.3% | 0.2% | 0.1% | 0.1% | 0.3% | 0.2% | 0.2% |
| SG&A / revenue | 57.7% | 57.9% | 54.6% | 51.4% | 50.6% | 45.9% | 46.8% | 53.5% | 53.1% | 63.7% |
| Efficiency | ||||||||||
| Days sales outstanding | 81.8 | 79.2 | 73.5 | 68.0 | 73.1 | 72.8 | 68.6 | 68.7 | 66.0 | 56.1 |
| Days of inventory on hand | 26.4 | 32.8 | 35.0 | 36.8 | 37.5 | 38.0 | 311.3 | 349.4 | 18.3 | 26.4 |
| Days payables outstanding | 117.6 | 116.1 | 103.3 | 64.2 | 49.7 | 44.0 | 47.8 | 68.2 | 92.7 | 88.9 |
| Cash conversion cycle (days) | -9.4 | -4.1 | 5.2 | 40.5 | 61.0 | 66.8 | 332.1 | 349.9 | -8.3 | -6.4 |
| Receivables turnover | 4.46 | 4.61 | 4.97 | 5.37 | 4.99 | 5.02 | 5.32 | 5.32 | 5.53 | 6.50 |
| Payables turnover | 3.10 | 3.14 | 3.53 | 5.68 | 7.35 | 8.30 | 7.63 | 5.35 | 3.94 | 4.10 |
| Inventory turnover | 13.83 | 11.14 | 10.42 | 9.92 | 9.73 | 9.60 | 1.17 | 1.04 | 19.90 | 13.80 |
| Asset turnover | 0.50 | 0.51 | 0.50 | 0.48 | 0.54 | 0.70 | 0.75 | 0.88 | 1.17 | 1.18 |
| Average receivables | $7.1M | $6.9M | $6.3M | $5.6M | $5.8M | $6.2M | $6.0M | $5.5M | $4.6M | $3.6M |
| Average payables | $2.4M | $2.5M | $2.4M | $1.5M | $1.2M | $1.2M | $1.3M | $1.6M | $1.7M | $1.4M |
| Average inventory | $533,248 | $713,290 | $810,054 | $886,222 | $924,266 | $1.0M | $8.6M | $8.2M | $337,854 | $418,375 |
| Intangibles / total assets | 4.5% | 4.4% | 4.8% | 26.3% | 29.9% | 7.5% | 7.4% | 7.7% | 0.9% | 1.3% |
Computed from CCEL's annual financial statements (latest annual report filed February 27, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
CCEL valuation and financial ratios
It ended the year with $11.6 million of debt and $3.3 million in cash and short-term investments, net debt of $8.3 million. It returned $3.4 million to shareholders: $3.2 million in dividends and $0.2 million in share buybacks, 65% of free cash flow.
See the CCEL income statement, the CCEL chart for price history, or the CCEL stock overview for the latest quote and news.
CCEL key metrics FAQ
What is Cryo-Cell International's EV/EBITDA?
Cryo-Cell International's enterprise value was 39.2 times EBITDA at the end of fiscal 2025 (enterprise value $43.0 million, EBITDA $1.1 million); the current EV/EBITDA is 50.9.
How much debt does Cryo-Cell International have?
Cryo-Cell International had total debt of $11.6 million at the end of fiscal 2025 and $8.3 million of net debt (7.53 times EBITDA).
What is Cryo-Cell International's dividend yield?
Cryo-Cell International paid $3.2 million in dividends in fiscal 2025 ($0.40 per share), a payout ratio of —.
Does Cryo-Cell International buy back its shares?
Yes. Cryo-Cell International spent $0.2 million on net share repurchases in fiscal 2025 Shares outstanding changed −1.8% over the year, to 8.1M..
What is Cryo-Cell International's free cash flow yield?
Cryo-Cell International generated $5.2 million of free cash flow in fiscal 2025, a free cash flow yield of 15.1% on its market value at year-end ($34.7 million).
What is Cryo-Cell International's current ratio?
Cryo-Cell International's current ratio was 0.59 at the end of fiscal 2025: current assets were 0.59 times current liabilities.